DAVID CHARLES SUBICH, MD
Osteopathic Medicine at Sturges Ave, Mansfield, OH

License number
Ohio 35.049208
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
120 Sturges Ave, Mansfield, OH 44903
Phone
(419) 522-3751
(419) 522-3903 (Fax)

Professional information

David C Subich Photo 1

Dr. David C Subich - MD (Doctor of Medicine)

Hospitals:
5210 Armour Rd STE 400, Columbus 31904
FAMILY MEDICAL CENTER OF TRINITY
2208 Duck Slough Blvd STE A, Trinity 34655
Medcentral Health System
335 Glessner Ave, Mansfield 44903
5210 Armour Rd STE 400, Columbus 31904
FAMILY MEDICAL CENTER OF TRINITY
2208 Duck Slough Blvd STE A, Trinity 34655
Medcentral Health System
335 Glessner Ave, Mansfield 44903
Education:
Medical Schools
University of Toledo
Graduated: 1982


David Subich Photo 2

Pharmaceutical Drug Sample Tracking And Control Method

US Patent:
2002016, Oct 31, 2002
Filed:
Feb 23, 2001
Appl. No.:
09/790385
Inventors:
David Subich - Mansfield OH, US
International Classification:
G06F017/60, A61B005/00
US Classification:
705/003000, 600/300000
Abstract:
A pharmaceutical drug sample tracking and control method. Pharmaceutical drug manufacturers send pharmaceutical drug samples bearing pharmaceutical drug sample indicia to dispensing locations where an indicia reader is used to read the pharmaceutical drug sample indicia into a dispensing location database. As pharmaceutical drug samples are dispensed to patients, an indicia reader is used to read the pharmaceutical drug sample indicia on pharmaceutical drug samples thus dispensed into the dispensing location database. Inventory software tracks inventory levels by subtracting pharmaceutical drug samples dispensed to patients from the previous recorded inventories. Pharmaceutical drug manufacturers can access inventory levels at dispensing locations remotely. Practitioners enter patient information, practitioner information, adverse reaction information and patient outcomes in the dispensing location database. Interested parties can access this information. Pharmaceutical drug manufacturers may instruct an intermediary to determine patient test group lists, patient newsletter lists, and lists of patients to whom drug recall and/or advisory information should be sent, and may further instruct the intermediary to send appropriate invitations, newsletters, and information to such patients, thereby maintaining patient confidentiality.